<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713176</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1248302</org_study_id>
    <nct_id>NCT04713176</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of mortality or ECMO patients</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Percentage of patients with mortality(ordinal scale of 8) or ECMO patients(ordinal scale of 7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery days</measure>
    <time_frame>Day 3,5,8,11,15,22,29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desirable of Outcome Ranking (DOOR)</measure>
    <time_frame>Day 15,29</time_frame>
    <description>The DOOR is scored by evaluating two items: ordinal scale and serious adverse events.&#xD;
DOORs are as follows: 1: Recovery (corresponding to the ordinal scale of 1, 2, or 3); 2: Improvement (reduced by more than 1 score of the ordinal scale compared to baseline) with no serious adverse events; 3: Improvement (reduced by more than 1 score of the ordinal scale compared to baseline) with serious adverse events; 4: No change (no change in the ordinal scale compared to baseline) with no serious adverse events; 5: No change (no change in the ordinal scale compared to baseline) with serious adverse event regardless of causality; 6: Deterioration (increased by more than 1 score of the ordinal scale compared to baseline); 7: Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization period</measure>
    <time_frame>Day 29</time_frame>
    <description>The duration of hospitalization (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Mortality</measure>
    <time_frame>Day 15,29</time_frame>
    <description>The percent of participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1022</enrollment>
  <condition>Severe COVID-19</condition>
  <arm_group>
    <arm_group_label>DWJ1248 with Remdesivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camostat mesylate 200 mg, Remdesivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Remdesivir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Remdesivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1248 with Remdesivir</intervention_name>
    <description>PO, 1 tablet of DWJ1248 TID(up to 14 days) IV, Remdesivir(up to 5 or 10 days)</description>
    <arm_group_label>DWJ1248 with Remdesivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo with Remdesivir</intervention_name>
    <description>PO, 1 tablet of placebo TID(up to 14 days) IV, Remdesivir(up to 5 or 10 days)</description>
    <arm_group_label>Placebo with Remdesivir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 19 as of the signed date in written consent&#xD;
&#xD;
          -  Subjects with COVID-19 according to RT-PCR test(within 10 days)&#xD;
&#xD;
          -  Subjects who need to be hospitalized and injected Remdesivir&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who cannot orally administer the investigational products&#xD;
&#xD;
          -  Subjects who requiring mechanical ventilation or ECMO&#xD;
&#xD;
          -  Acute Respiratory Distress Syndrome(ARDS), shock, multiple organ dysfunction syndrome&#xD;
&#xD;
          -  Subjects who need administration of immunosuppressants&#xD;
&#xD;
          -  Subjects who are allergic or sensitive to investigational products or its ingredients&#xD;
&#xD;
          -  Crcl &lt; 30 mL/min or eGFR &lt; 30 mL/min/1.73m^2&#xD;
&#xD;
          -  AST or ALT &gt;= 5xULN&#xD;
&#xD;
          -  Subjects who have been identified with uncontrolled concomitant diseases or&#xD;
             conditions, including significant mental illness and social conditions, that may&#xD;
             affect compliance with clinical trial procedures according to the determination of the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>04564</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Hyun Jeon</last_name>
      <email>mdjjh@nmc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

